ENINGIOMAS are benign tumors that arise from cranial and spinal arachnoid cells. For most of these lesions, surgery provides effective and sufficient clinical results. However, some meningiomas recur or are resected subtotally because of anatomical problems such as their location at the skull base. To date, the only effective treatment for such recurrent and/or subtotally resected meningiomas has been limited to radiotherapy. 4, 16 Meningiomas occur predominantly in women, and often contain steroid receptors such as estrogen and progesterone receptors. 2, 19 Additionally, in many in vitro studies 2, 10, 18, 19 it has been suggested that hormone therapy is a promising option for treatment of meningioma, but no hormonal agents except tamoxifen 6,14 and mifepristone 7 have been shown clinically to contribute to the regression of a meningioma. In this report, we describe a case of presumed meningioma that regressed as a result of treatment with the antiestrogen agent mepitiostane.
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Case Report This 68-year-old woman underwent a distal gastrectomy for gastric cancer (papillary adenocarcinoma, Stage I) on August 31, 1994. As part of a staging examination of the gastric cancer, head CT scans were obtained, and these revealed a brain tumor. Consulting neurosurgeons diagnosed the tumor as a presumed falx meningioma because it was a homogeneously enhanced mass with a smooth surface and it was attached to the posterior falx with a dural tail sign (Fig. 1) . Informed consent was given on the patient's behalf for surgery of the gastric cancer but not for the meningioma because she had no associated clinical symptoms and her family strongly requested us not to inform her of the presence of the brain tumor. After gastrectomy, she received tegafur as adjuvant chemotherapy until February 1996, when she was readmitted to our hospital because of loss of appetite and emaciation but with no recurrence of the gastric cancer. At that time, tegafur was discontinued and administration of mepitiostane 17 was begun in an attempt to improve her general condition. She was discharged from our hospital on July 27, 1996, and was maintained on mepitiostane. On August 25, 1996, we obtained a CT scan of the brain, which showed no progression or regression of the meningioma (Fig. 2) . On June 18, 1998, the patient was again admitted to our hospital because of loss of appetite and emaciation. Admission CT scans of her abdomen and chest showed no recurrence of gastric cancer. However, a head CT scan demonstrated a marked (73%) regression of the meningioma (Fig. 3) . At that time, serum levels of estrone, estradiol, estriol, and testosterone were less than 10 pg/ml, 14.6 pg/ml, less than 5 pg/ml, and 13.1 ng/ml, respectively. The patient recovered from her loss of appetite and emaciation with intravenous hyperalimentation, and was discharged on July 31, 1998. She continued to receive mepitiostane and had no evidence of regrowth of the meningioma as of February 1999.
Discussion
Radiotherapy provides the only effective alternative to surgery in the treatment of meningiomas. The other alternatives to surgery such as chemotherapy 12 and immunotherapy 11 have not yet become standard for the treatment of meningiomas.
Many authors 2, 10, 18, 19 have suggested that antiestrogen or antiprogesterone therapy may be effective for meningiomas, based on the fact that these tumors often contain estrogen and progesterone receptors. However, in clinical trials 6, 8, 14, 15 only two objective responses to tamoxifen (that is, Ͼ 50% reduction in tumor size) 6, 14 have been reported, and no objective response to other hormonal agents such as MPA and mifepristone has been reported.
In this case, we had not intended to treat the presumed meningioma with the antiestrogen agent mepitiostane; it was administered to improve the general condition of the patient. 17 The use of mepitiostane for approximately 2 years failed to achieve this goal, but incidentally resulted in a marked regression of the meningioma. When we noticed the tumor regression, we initially thought that the marked decrease in serum estrogen levels caused by weight loss might have contributed (that is, spontaneous regression). However, on further investigation we came to believe that the meningioma should not have regressed with the decrease in serum estrogen levels because the patient's serum levels of estradiol, the main estrogen, were high for her age.
Bernstein, et al., 1 reported an incidental regression of meningioma with administration of 5-fluorouracil, folinic acid, and levamisole for the treatment of rectal cancer.
Our patient received tegafur as adjuvant chemotherapy for gastric cancer, which might also have contributed to the regression of the meningioma. However, after she had been treated with tegafur for approximately 2 years, a plain CT scan of the brain showed no regression of the meningioma. Thereafter, the patient received no other chemotherapeutic and/or hormonal agents except mepitiostane. Thus, it is reasonable to assume that the meningioma regressed as a result of the antiestrogen mepitiostane.
Of the many antiestrogen agents now available, tamoxifen is the most commonly used in patients with breast cancer because of its high antitumor activity and few adverse effects. On the other hand, tamoxifen is known to have not only antiestrogenic properties, but also weak es- trogenic activity. 5 Jay, et al., 10 reported that tamoxifen accelerated the progression of meningioma cells in vitro. However, it is still unclear whether meningiomas are clinically affected by the weak estrogenic activity of tamoxifen.
Of the two steroid receptors for estrogen and progesterone, meningiomas often contain more progesterone than estrogen receptors. 2, 19 Markwalder and colleagues 13, 15 reported that MPA is an attractive therapy for meningioma because administration of this agent downregulates progesterone receptor contents and inhibits the growth of meningioma as measured by Ki-67. However, they and Jääs-keläinen, et al., 8 reported that no meningioma actually responded to MPA. Grunberg, et al., 7 reported that an objective response was found in five of 14 patients with unresectable meningioma after treatment with the antiprogesterone agent mifepristone. All five responders, however, had only minor decreases in tumor size.
In our case, a 2-year maintenance on mepitiostane resulted in a marked regression of the meningioma. On the other hand, administration of mepitiostane for approximately 6 months initially caused no marked change in the meningioma. These findings indicate that mepitiostane should be administered for a longer period for the treatment of meningioma. We think that long-term administration of this agent is preferable for the following reasons. First, the onset of tumor regression with hormone therapy is generally slower than that with chemotherapy in breast cancer, and perhaps also in meningioma. 6, 14 Second, estrogen receptor levels in meningioma are much lower than those in breast cancer. 2, 19 Third, a disruption of hormone therapy may accelerate the regrowth of meningioma. Finally, the adverse effects 9 of mepitiostane are very mild.
Conclusions This is the first reported case of a presumed meningioma that regressed markedly after administration of the antiestrogen agent mepitiostane. Because it has already been proven that the efficacy of tamoxifen and mifepristone against meningioma is limited, a prospective study in which mepitiostane is used against recurrent and/or unresectable meningioma should be undertaken.
